Uniss MasSpec Pen platform for clinical and translational research
20 Nov 2023
In this video, Thermo Fisher Scientific introduces the MasSpec Pen™ platform, a handheld mass spectrometry device designed for the rapid and non-destructive diagnosis of human cancer tissues. The device allows for controlled and automated delivery of a discrete water droplet to a tissue surface, facilitating efficient extraction of biomolecules. These extracted biomolecules are then delivered to a mass spectrometer for molecular analysis. The results presented in the video suggest that the MasSpec Pen has the potential to be utilized as a clinical and intra-operative tool for both ex vivo and in vivo cancer diagnosis.
About the company
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
